Drug
Men1611
Men1611: highest development phase Phase 1/2, developed by Menarini. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Menarini
Trials
| Drug | Phase | Indication |
|---|---|---|
| MEN1611 NCT04495621 | Phase 1/2 | Metastatic Colorectal Cancer |
| MEN1611 NCT03767335 | Phase 1 | Advanced or Metastatic Breast Cancer |
Latest
No recent events.
Follow Men1611 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.